Anti-PKA-RIA Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against phosphorylation sites of cAMP-dependent protein kinase type I-alpha regulatory subunit (PRKAR1B), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential
UniProt
Q9DBC7
Size
100ug
Cat. #
RP1PKARIA

In stock

SKU
RP-PKARIA

Options

As low as: $130.00

Target Overview

The cAMP-dependent protein kinase type I-alpha regulatory subunit (PKA-RIA, encoded by PRKAR1B in humans, Prkar1a in mice) is a regulatory component of protein kinase A (PKA), a serine/threonine kinase central to cAMP signaling. PKA holoenzymes consist of two regulatory (R) subunits bound to two catalytic (C) subunits in an inactive state. Binding of cAMP to the R subunits induces conformational changes that release active catalytic subunits. PRKAR1B encodes the type I-beta regulatory isoform, which localizes to the cell membrane and cytoplasm, where it modulates substrate accessibility and spatial PKA activity. The regulatory subunit undergoes N-terminal processing and phosphorylation at multiple sites that fine-tune kinase responsiveness to cAMP. Researchers study PKA-RIA to understand cAMP-mediated signaling in development, metabolism, and oncogenesis. UniProt accession Q9DBC7 corresponds to the mouse Prkar1a sequence (381 amino acids).

Background

PKA is a master regulator of diverse cellular processes including glycogen metabolism, gene transcription, cell cycle progression, and apoptosis. The type I regulatory subunits (RIα and RIβ) differ from type II isoforms in cAMP sensitivity, subcellular localization, and tissue distribution. PRKAR1B is highly expressed in brain, testis, and certain tumor types, where it contributes to spatially restricted PKA signaling microdomains through A-kinase anchoring protein (AKAP) interactions. Dysregulation of PRKAR1B has been implicated in neurodevelopmental disorders and cancer progression. Burkart et al. (2026) recently expanded the phenotypic spectrum of PRKAR1B-related Marbach-Schaaf neurodevelopmental syndrome, describing additional cases with intellectual disability, hypotonia, and dysmorphic features associated with loss-of-function variants. In oncology, Zhao et al. (2026) identified PRKAR1B as a candidate biomarker in head and neck squamous cell carcinoma, where its expression correlates with tumor immunity, proliferation, and migration indices. Recent structural and biochemical studies have clarified allosteric mechanisms governing PKA activation. Wu et al. (2025) demonstrated that N3A motifs in the RIβ subunit mediate crosstalk between cAMP and ATP binding, revealing how nucleotide occupancy at regulatory sites influences catalytic subunit release kinetics. These findings inform the design of PKA modulators and help interpret phosphorylation-dependent signaling outputs. Antibodies targeting phosphorylation sites on PKA-RIA enable researchers to monitor kinase activation state and subcellular redistribution in response to hormonal or pharmacological stimuli.

References

  1. Zhao P et al (2026) PRKAR1B as an oncogenic biomarker for diagnostic and prognostic stratification of tumor immunity, proliferation, and migration in head and neck squamous cell carcinoma. Front Immunol. PubMed · 10.3389/fimmu.2026.1770459
  2. Burkart S et al (2026) Expansion of the Phenotypic and Genotypic Spectrum for PRKAR1B-Related Marbach-Schaaf Neurodevelopmental Syndrome: A Case Series. Clin Genet. PubMed · 10.1111/cge.70094
  3. Wu J et al (2025) N3A motifs in RIβ mediate allosteric crosstalk between cAMP and ATP in PKA activation. Protein Sci. PubMed · 10.1002/pro.70332
  4. Ma Y et al (2025) Sequential denaturation and protein precipitation assay (SDPP) improves the sensitivity for ligand target identification at the proteome level. Anal Chim Acta. PubMed · 10.1016/j.aca.2025.344722
  5. Devaux A et al (2025) Identification of microprotein-coding intronic polyadenylation isoforms and function in genotoxic anticancer drug response. Genome Biol. PubMed · 10.1186/s13059-025-03829-7

Additional Specifications

Gene Symbol PRKAR1B
UniProt ID Q9DBC7
Host Species Rabbit
Species Reactivity Validated- Human
Potential
Pack Size 100ug
Immunogen Immunogen is proprietary and confidential. Immunogen generated in amino acid region 1-50.
Alternate Names PRKAR1B, Prkar1a, cAMP-dependent protein kinase type I-alpha regulatory subunit, PKA type I-alpha regulatory subunit, PKA RIα, Protein kinase A RIα, cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed

Frequently Asked Questions

What is the expected molecular weight for PKA-RIA on a Western blot?

The type I-alpha regulatory subunit of PKA typically migrates at approximately 43 kDa on SDS-PAGE, corresponding to the full-length PRKAR1A protein. You may observe doublets or slight shifts due to phosphorylation at multiple regulatory sites or N-terminal processing events. In some cell types with high PKA activity, you might detect minor proteolytic fragments below 43 kDa. Always run a positive control lysate from tissues or cells with high cAMP signaling activity, such as brain, heart, or endocrine tissues, to confirm the expected band pattern before analyzing experimental samples.

How do I distinguish PKA-RIA from PKA-RIB on a Western blot?

PKA-RIA (PRKAR1A gene product, ~43 kDa) and PKA-RIB (PRKAR1B gene product, ~49 kDa) migrate at different molecular weights, which aids identification. This antibody was raised against human PKA-RIA and is validated specifically for that isoform. If you need to assess both type I regulatory subunits simultaneously, run separate blots with isoform-specific antibodies rather than relying on band size alone, since post-translational modifications can alter migration. RIA predominates in most somatic tissues, whereas RIB shows enrichment in brain, adipose, and certain cancer cell lines.

Does this PKA-RIA antibody cross-react with mouse or rat samples?

The antibody is validated in human samples and shows predicted cross-reactivity with mouse and rat based on sequence homology between human PRKAR1A and rodent Prkar1a orthologs, which share greater than 95 percent amino acid identity in the immunogen region. However, you should confirm reactivity and optimal dilution empirically with your specific rodent tissue or cell lysate. Start at the recommended 1:1000 dilution for Western blot and adjust based on signal strength. Brain, heart, and testis lysates serve as useful positive controls for rodent samples due to high endogenous PKA-RIA expression.

What dilution should I start with for immunofluorescence with this PKA-RIA antibody?

Although this antibody is validated for Western blot at 1:1000, immunofluorescence typically requires higher antibody concentrations. A reasonable starting dilution for IF is between 1:100 and 1:200, then titrate based on signal-to-noise ratio in your specific cell type. PKA-RIA localizes primarily to the cytoplasm and cell membrane under basal conditions, so expect diffuse cytoplasmic staining with possible membrane enrichment. Include a secondary-antibody-only control to assess background, and consider treating cells with forskolin or IBMX to elevate cAMP and potentially redistribute PKA subunits if studying dynamic localization.

What are good positive and negative control tissues for PKA-RIA Western blots?

PKA-RIA is widely expressed, making true negative tissues rare. Brain, heart, skeletal muscle, and endocrine tissues such as adrenal or pancreas show robust expression and serve as excellent positive controls. For a relative negative control, consider terminally differentiated cells with lower proliferative signaling, though complete absence is uncommon. Alternatively, use siRNA or CRISPR knockdown cell lines targeting PRKAR1A as a functional negative control to confirm antibody specificity. Including both a high-expression tissue and a knockdown sample on the same blot provides the most convincing validation of signal specificity.

Can I use this antibody to detect PKA-RIA in immunohistochemistry on FFPE sections?

this antibody is validated for Western blot; IHC validation is in progress applications, making it suitable for formalin-fixed paraffin-embedded tissue sections. Antigen retrieval is typically required; citrate buffer (pH 6.0) heat-mediated retrieval is a standard starting method for PKA regulatory subunits. Expect cytoplasmic and membranous staining patterns in epithelial and stromal cells. Optimal antibody dilution for IHC often differs from Western blot and may range from 1:50 to 1:200. Titrate on your specific tissue type and include appropriate positive control sections such as normal brain or cardiac tissue to establish staining conditions before scoring experimental samples.

How should I store this PKA-RIA antibody and what is the typical shelf life?

Store the antibody at -20°C in single-use aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The product ships as 100 µg and typically remains stable for at least 12 months from receipt when stored correctly. If you use the antibody frequently, a working aliquot can be kept at 4°C for up to one month; add sodium azide (0.02 to 0.05 percent final) as a preservative if storing diluted stocks. Avoid prolonged exposure to room temperature. Centrifuge briefly before use if you observe particulates, which can cause high background in immunofluorescence.

What sample preparation considerations are important for detecting PKA-RIA by Western blot?

Use fresh or snap-frozen lysates when possible, as PKA regulatory subunits can undergo proteolysis during prolonged sample handling. Include protease inhibitors (AEBSF, aprotinin, leupeptin) and phosphatase inhibitors (sodium fluoride, sodium orthovanadate) in lysis buffer, since PKA-RIA is phosphorylated at multiple sites that affect its electrophoretic mobility. RIPA or NP-40 lysis buffers work well for extracting cytoplasmic and membrane-associated pools. Load 20 to 40 µg total protein per lane as a starting point. Avoid boiling samples excessively; five minutes at 95°C is sufficient and reduces aggregation that can smear the 43 kDa band.

Validation imagery coming soon

Western blot validation figures for RP-PKARIA will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

Also known as:

  • PRKAR1B
  • Prkar1a
  • cAMP-dependent protein kinase type I-alpha regulatory subunit
  • PKA type I-alpha regulatory subunit
  • PKA RIα
  • Protein kinase A RIα
  • cAMP-dependent protein kinase type I-alpha regulatory subunit
  • N-terminally processed
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →